Literature DB >> 28628529

Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure.

Suzanne M McCluskey1, Yap Boum, Nicholas Musinguzi, Jessica E Haberer, Jeffrey N Martin, Peter W Hunt, Vincent C Marconi, David R Bangsberg, Mark J Siedner.   

Abstract

BACKGROUND: The World Health Organization defines HIV virologic failure as 2 consecutive viral loads >1000 copies/mL, measured 3-6 months apart, with interval adherence support. We sought to empirically evaluate these guidelines using data from an observational cohort.
SETTING: The Uganda AIDS Rural Treatment Outcomes study observed adults with HIV in southwestern Uganda from the time of antiretroviral therapy (ART) initiation and monitored adherence with electronic pill bottles.
METHODS: We included participants on ART with a detectable HIV RNA viral load and who remained on the same regimen until the subsequent measurement. We fit logistic regression models with viral resuppression as the outcome of interest and both initial viral load level and average adherence as predictors of interest.
RESULTS: We analyzed 139 events. Median ART duration was 0.92 years, and 100% were on a nonnucleoside reverse-transcriptase inhibitor-based regimen. Viral resuppression occurred in 88% of those with initial HIV RNA <1000 copies/mL and 42% if HIV RNA was >1000 copies/mL (P <0.001). Adherence after detectable viremia predicted viral resuppression for those with HIV RNA <1000 copies/mL (P = 0.011) but was not associated with resuppression for those with HIV RNA >1000 copies/mL (P = 0.894; interaction term P = 0.077).
CONCLUSIONS: Among patients on ART with detectable HIV RNA >1000 copies/mL who remain on the same regimen, only 42% resuppressed at next measurement, and there was no association between interval adherence and viral resuppression. These data support consideration of resistance testing to help guide management of virologic failure in resource-limited settings.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28628529      PMCID: PMC5597473          DOI: 10.1097/QAI.0000000000001479

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  26 in total

1.  Optimal recall period and response task for self-reported HIV medication adherence.

Authors:  Minyi Lu; Steven A Safren; Paul R Skolnik; William H Rogers; William Coady; Helene Hardy; Ira B Wilson
Journal:  AIDS Behav       Date:  2007-06-19

2.  Drug susceptibility and resistance mutations after first-line failure in resource limited settings.

Authors:  Carole L Wallis; Evgenia Aga; Heather Ribaudo; Shanmugam Saravanan; Michael Norton; Wendy Stevens; Nagalingeswaran Kumarasamy; John Bartlett; David Katzenstein
Journal:  Clin Infect Dis       Date:  2014-05-01       Impact factor: 9.079

3.  Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting.

Authors:  Sheri D Weiser; Alexander C Tsai; Reshma Gupta; Edward A Frongillo; Annet Kawuma; Jude Senkungu; Peter W Hunt; Nneka I Emenyonu; Jennifer E Mattson; Jeffrey N Martin; David R Bangsberg
Journal:  AIDS       Date:  2012-01-02       Impact factor: 4.177

4.  Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.

Authors:  Jessica E Haberer; Nicholas Musinguzi; Yap Boum; Mark J Siedner; A Rain Mocello; Peter W Hunt; Jeffrey N Martin; David R Bangsberg
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

5.  Real-time adherence monitoring for HIV antiretroviral therapy.

Authors:  Jessica E Haberer; Josh Kahane; Isaac Kigozi; Nneka Emenyonu; Peter Hunt; Jeffrey Martin; David R Bangsberg
Journal:  AIDS Behav       Date:  2010-12

6.  Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Authors:  Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

7.  Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.

Authors:  Claudie Laprise; Alexandra de Pokomandy; Jean-Guy Baril; Serge Dufresne; Helen Trottier
Journal:  Clin Infect Dis       Date:  2013-08-14       Impact factor: 9.079

8.  Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children.

Authors:  Jessica E Haberer; Julius Kiwanuka; Denis Nansera; Kathleen Ragland; Claude Mellins; David R Bangsberg
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

Review 9.  Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis.

Authors:  Pieter W Smit; Kimberly A Sollis; Susan Fiscus; Nathan Ford; Marco Vitoria; Shaffiq Essajee; David Barnett; Ben Cheng; Suzanne M Crowe; Thomas Denny; Alan Landay; Wendy Stevens; Vincent Habiyambere; Joseph H Perriens; Rosanna W Peeling
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

10.  Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.

Authors:  Jean d'Amour Ndahimana; David J Riedel; Mutagoma Mwumvaneza; Dieudone Sebuhoro; Jean Claude Uwimbabazi; Marthe Kubwimana; Jules Mugabo; Augustin Mulindabigwi; Catherine Kirk; Steve Kanters; Jamie I Forrest; Linda L Jagodzinski; Sheila A Peel; Muhayimpundu Ribakare; Robert R Redfield; Sabin Nsanzimana
Journal:  Trop Med Int Health       Date:  2016-06-13       Impact factor: 2.622

View more
  11 in total

1.  Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.

Authors:  Caitlin M Dugdale; Andrea L Ciaranello; Linda-Gail Bekker; Madeline E Stern; Landon Myer; Robin Wood; Paul E Sax; Elaine J Abrams; Kenneth A Freedberg; Rochelle P Walensky
Journal:  Ann Intern Med       Date:  2019-04-02       Impact factor: 25.391

Review 2.  Point-of-Care HIV Viral Load Testing: an Essential Tool for a Sustainable Global HIV/AIDS Response.

Authors:  Paul K Drain; Jienchi Dorward; Andrew Bender; Lorraine Lillis; Francesco Marinucci; Jilian Sacks; Anna Bershteyn; David S Boyle; Jonathan D Posner; Nigel Garrett
Journal:  Clin Microbiol Rev       Date:  2019-05-15       Impact factor: 26.132

3.  Urgent need to improve programmatic management of patients with HIV failing first-line antiretroviral therapy.

Authors:  H Sunpath; T J Hatlen; M-Y S Moosa; R A Murphy; M Siedner; K Naidoo
Journal:  Public Health Action       Date:  2020-12-21

4.  Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa.

Authors:  Helen Bell Gorrod; Richard Court; Michael Schomaker; Gary Maartens; Richard A Murphy
Journal:  J Acquir Immune Defic Syndr       Date:  2020-05-01       Impact factor: 3.771

5.  HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.

Authors:  Adriaan E Basson; Salome Charalambous; Christopher J Hoffmann; Lynn Morris
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

6.  HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis.

Authors:  Nathan Ford; Catherine Orrell; Zara Shubber; Tsitsi Apollo; Lara Vojnov
Journal:  J Int AIDS Soc       Date:  2019-11       Impact factor: 5.396

7.  Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa.

Authors:  Giovanni Villa; Adam Abdullahi; Dorcas Owusu; Colette Smith; Marilyn Azumah; Laila Sayeed; Harrison Austin; Dominic Awuah; Apostolos Beloukas; David Chadwick; Richard Phillips; Anna Maria Geretti
Journal:  EClinicalMedicine       Date:  2020-01-05

8.  High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania - A prospective cohort study.

Authors:  Rahel E Bircher; Alex J Ntamatungiro; Tracy R Glass; Dorcas Mnzava; Amina Nyuri; Herry Mapesi; Daniel H Paris; Manuel Battegay; Thomas Klimkait; Maja Weisser
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

9.  Scaling up HIV viral load monitoring in Manicaland, Zimbabwe: challenges and opportunities from the field.

Authors:  B Nyagadza; N Kudya; E Mbofana; S Masaka; D Garone; C-Y Chen; A Mulingwa; C Uzande; P Isaakidis; Z Ndlovu
Journal:  Public Health Action       Date:  2019-12-21

10.  Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.

Authors:  Lucas E Hermans; Sergio Carmona; Monique Nijhuis; Hugo A Tempelman; Douglas D Richman; Michelle Moorhouse; Diederick E Grobbee; Willem D F Venter; Annemarie M J Wensing
Journal:  PLoS Med       Date:  2020-02-25       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.